| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Neuralink | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.34B | Series E | 6/2/2025 | $324.5M | $9.62B | $50.50 | ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed Venture Partners, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, Vy Capital, K2 Global, K5 Global, Goanna Capital, Integra Groupe, LDV Partners, Mac Equity, Moonshots Capital, Neman Family Office, Pittco Management, POLYInvest, Realm Capital Ventures, Selective VC, Seven Rivers Capital, Talok Capital, Team Ignite Ventures, Transform Investments, Trousdale Ventures, Unmatched Ventures, Vibhu Venture Partners, VU Venture Partners | ||||
 | OURA | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $148.20K | -- | 1 | -- | Not available | -- | -- | $1.65B | Series E | 10/14/2025 | $900M | $11B | $53.57 | Fidelity, ICONIQ, Whale Rock Capital, Atreides, Lateralus Holdings, Matter Venture Partners | ||||
 | OpenEvidence | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $3.05M | -- | 3 | -- | Not available | -- | -- | $893.23M | Series D-2 | 4/14/2026 | $192.5M | $12.19B | $487.38 | Undisclosed Investors | ||||
 | Abridge | Healthcare Healthcare Software | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $386.63K | -- | 1 | $200.00 | +17.65% | +26.20% | $773.91M | Series E | 6/24/2025 | $315.93M | $5.3B | $158.48 | Andreessen Horowitz, Khosla Ventures, Archerman Capital, California Health Care Foundation, Catalio Capital Management, Eli Lilly, Emerson Collective, Harper Ventures, Soma Capital, WndrCo | ||||
 | Ro | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $884.86M | Series D-1 | 2/15/2022 | $100M | $7.19B | $15.33 | ShawSpring Partners, General Catalyst, FirstMark Capital, TQ Ventures, SignalFire, BoxGroup, The Chernin Group, Initialized Capital, Altimeter Capital, Baupost Group, Seven Seven Six | ||||
 | ZocDoc | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $102.00K | -- | 1 | -- | $5.00 | +0.00% | +0.00% | $1.15B | Series D-2 | 2/11/2021 | $100M | $2.62B | $29.29 | Francisco Partners | ||||
 | Precision Neuroscience | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $1.84M | -- | 5 | Not available | -- | -- | $466.59M | Series D | 9/11/2026 | $287.5M | $1.04B | $7.20 | Undisclosed Investors | ||||
 | Altos Labs | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $210.88K | -- | 1 | Not available | -- | -- | $11.13B | Series C | 2/14/2024 | $1.5B | $6.33B | $25.02 | Undisclosed Investors | ||||
 | Enveda | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $807.14M | Series E | 9/9/2026 | $311M | $1.61B | $10.38 | Undisclosed Investors | ||||
 | Chai Discovery | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $100.13K | -- | 1 | -- | Not available | -- | -- | $620.17M | Series C | 7/14/2026 | $400M | $3.8B | $178.05 | Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, Yosemite, Scribble Ventures | ||||
 | Virta Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $395.18M | Series F | 12/29/2025 | $30.15M | $1.2B | $1.46 | Undisclosed Investors | ||||
 | Included Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $529.32M | Series E | 9/9/2020 | $103.04M | $1.13B | $3.22 | The Carlyle Group | ||||
 | Colossal Biosciences | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $490.00K | -- | 1 | -- | Not available | -- | -- | $620.64M | Series C | 2/3/2026 | $380M | $10.32B | $24.89 | TWG Global, Peter Jackson, US Innovative Technology Fund, Robert Nelsen, United Arab Emirates | ||||
 | Benchling | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $412.69M | Series F | 11/18/2021 | $89.62M | $6.1B | $32.70 | Franklin Templeton, Altimeter Capital, Tiger Global, Lone Pine Capital, Artisanal Ventures, Rogue Capital, Section Partners, SNR, SV Angel, Y Combinator | ||||
 | Noom | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.32B | Series F | 5/25/2021 | $525.46M | $3.66B | $60.34 | Silver Lake, Oak HC/FT, Temasek, Novo Holdings, Sequoia Capital, RRE, Samsung Ventures | ||||
 | Rula | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $3.8M | -- | 1 | Not available | -- | -- | $268.55M | Series C-1 | 2/17/2026 | $6.24M | $2.4B | $11.32 | Undisclosed Investors | ||||
 | Spring Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $570.61M | Series D Aegis | 4/30/2026 | $130M | $3.52B | $69.22 | Undisclosed Investors | ||||
 | Transcarent | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.13B | Series D-1 | 4/7/2025 | $700M | $3.16B | $20.48 | Undisclosed Investors | ||||
 | Xaira Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1B | Series A | 4/23/2024 | $500M | $2.65B | $2.50 | ARCH Venture Partners, Foresite Capital, F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, Parker Institute for Cancer Immunotherapy, Byers Capital, Rsquared, SV Angel, AIM13, Breyer Capital, Deviation Capital, Foresite Labs, JSL Health Capital, Longwood Fund, Sahsen Ventures, WRF Capital | ||||
 | Formation Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $744.65K | -- | 2 | Not available | -- | -- | $3.38B | Series D | 6/26/2024 | $372M | $1.48B | $8.18 | Andreessen Horowitz, Sanofi, Sequoia Capital, Thrive Capital, Emerson Collective, Lachy Groom, SV Angel Growth, FPV Ventures | ||||
 | Pathos | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $732M | Series E | 8/21/2026 | $300M | $2.97B | $13.24 | Undisclosed Investors | ||||
 | Sword Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $540.19M | Junior | 1/16/2026 | $175.33M | $4.15B | $71.51 | Undisclosed Investors | ||||
 | Cellares | Healthcare Healthcare Providers & Services | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $639.25M | Series D-1 | 5/6/2026 | $26.49M | $1.4B | $11.99 | Undisclosed Investors | ||||
 | NewLimit | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $100.04K | -- | 1 | -- | Not available | -- | -- | $682.09M | Series C-2 | 6/2/2026 | $210M | $3.1B | $53.47 | Founders Fund, Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, NFDG, Valor Equity Partners, Lilly Ventures, Human Capital | ||||